Can engineered immune cells outsmart Hard-to-Treat blood cancers?

NCT ID NCT05457010

Ongoing ⭐️ CURE ⭐️ Sponsor: Arcellx, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental cell therapy for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to recognize a specific protein on cancer cells, along with a targeting molecule that helps them bind and attack. The main goals are to assess safety, find the right dose, and see if the treatment shows any signs of fighting the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A combination of genetically modified immune cells (ARC-T cells) and a targeting protein (SPRX002) that helps these cells find and attack cancer cells.
What this could lead to: If successful, this could lead to a new treatment option for people with hard-to-treat blood cancers, potentially offering a path to remission.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet proven. There are risks of side effects, including severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Montefiore Einstein Cancer Center

New Rochelle, New York, 10801, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.